1. Home
  2. FC vs THAR Comparison

FC vs THAR Comparison

Compare FC & THAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Franklin Covey Company

FC

Franklin Covey Company

HOLD

Current Price

$17.42

Market Cap

228.5M

ML Signal

HOLD

Logo Tharimmune Inc.

THAR

Tharimmune Inc.

HOLD

Current Price

$4.75

Market Cap

193.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FC
THAR
Founded
1983
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Other Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
228.5M
193.3M
IPO Year
1992
2022

Fundamental Metrics

Financial Performance
Metric
FC
THAR
Price
$17.42
$4.75
Analyst Decision
Strong Buy
Analyst Count
2
0
Target Price
$26.00
N/A
AVG Volume (30 Days)
129.0K
1.5M
Earning Date
04-01-2026
03-25-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$262,026,000.00
N/A
Revenue This Year
$3.02
N/A
Revenue Next Year
$3.66
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$14.04
$0.95
52 Week High
$36.55
$9.08

Technical Indicators

Market Signals
Indicator
FC
THAR
Relative Strength Index (RSI) 34.00 60.77
Support Level $18.42 $4.15
Resistance Level $18.92 $4.83
Average True Range (ATR) 0.96 0.61
MACD -0.42 -0.02
Stochastic Oscillator 1.13 48.64

Price Performance

Historical Comparison
FC
THAR

About FC Franklin Covey Company

Franklin Covey Co is a company focused on organizational performance improvement. It operates in the business segments of North America, International Direct Offices, International Licensees, Education Division. The company derives revenue from providing training and consulting services and through the sale of books, audio media, and other related products. It has a business presence in Australia, New Zealand, China, Japan, the United Kingdom, Ireland, and Other countries.

About THAR Tharimmune Inc.

Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.

Share on Social Networks: